Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection

Phase 2Pevifoscorvir SodiumPositive

AI Analysis

Summary

Aligos Therapeutics announced the completion of enrollment in the Phase 2 B-SUPREME study of pevifoscorvir sodium for chronic hepatitis B virus infection. The enrollment milestone represents progress toward potential future data readout and regulatory advancement.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Enrollment completion announced

Importance:6/10

Sentiment:

0.50

clinical trialPhase 2enrollment completionchronic HBVantiviral

Related Companies

$ALGS

Read the original article

Published by yahoo_finance on July 13, 2026 12:00 PM

Read Original